Although both findings insufficiently characterize the ACPA-negative RA patients who will achieve SDFR, these findings prompted the hypothesis that ACPA-negative RA patients achieving SDFR might also have a stronger biomarker response after DMARD treatment. Here, PRTN3 is linked to rheumatoid arthritis.